Financials data is unavailable for this security.
View more
Year on year D.Western Therapeutics Institute Inc 's revenues fell -4.40%from 448.10m to 428.36m. In addition, the company has been unable to reduce the cost of goods sold, selling, general and administrative expenses and interest paid (all as a percentage of sales). This has contributed to a 89.07% reduction in net income from a loss of 429.69m to a larger loss of 812.41m.
Gross margin | 91.27% |
---|---|
Net profit margin | -235.62% |
Operating margin | -233.50% |
Return on assets | -44.77% |
---|---|
Return on equity | -81.33% |
Return on investment | -47.81% |
More ▼
Cash flow in JPYView more
In 2023, cash reserves at D.Western Therapeutics Institute Inc fell by 467.40m. Cash Flow from Financing totalled 134.47m or 31.39% of revenues. In addition the company used 586.82m for operations while cash used for investing totalled 15.25m.
Cash flow per share | -32.44 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 25.80 |
---|---|
Tangible book value per share | 23.83 |
More ▼
Balance sheet in JPYView more
Current ratio | 19.32 |
---|---|
Quick ratio | 18.24 |
Total debt/total equity | 1.30 |
---|---|
Total debt/total capital | 0.5644 |
More ▼
Growth rates in JPY
Year on year, growth in earnings per share excluding extraordinary items dropped -76.34%.
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -82.30 |